Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Gilberto de Castro, Naiyer A. Rizvi, Peter Schmid, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 1, pp. 106-119
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Tremelimumab: First Approval
Susan J. Keam
Drugs (2022) Vol. 83, Iss. 1, pp. 93-102
Open Access | Times Cited: 72
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Lavanya Sivapalan, Joseph C. Murray, Jenna VanLiere Canzoniero, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005924-e005924
Open Access | Times Cited: 66
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 4, pp. 705-710
Open Access | Times Cited: 49
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
Roberto Ferrara, Martina Imbimbo, Reem Malouf, et al.
Cochrane library (2021) Vol. 2021, Iss. 4
Open Access | Times Cited: 94
Immunotherapy-based combinations in metastatic NSCLC
Aakash Desai, Solange Peters
Cancer Treatment Reviews (2023) Vol. 116, pp. 102545-102545
Open Access | Times Cited: 36
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Jaume Capdevila, Jorge Hernando, Àlex Teulé, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
Molly Li, Kevin Mok, Tony Mok
Annals of Translational Medicine (2023) Vol. 11, Iss. 10, pp. 358-358
Open Access | Times Cited: 22
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study
Mingchao Xie, Miljenka Vuko, Jaime Rodriguez‐Canales, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis
Shuang Wang, Meng‐Ting Cai, Yajun Xiong, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access | Times Cited: 1
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology (2024) Vol. 20, Iss. 1, pp. 76-93
Open Access | Times Cited: 7
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Mahesh Koirala, Mario DiPaola
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1801-1801
Open Access | Times Cited: 6
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
Roberto Ferrara, Martina Imbimbo, Reem Malouf, et al.
Cochrane library (2020)
Open Access | Times Cited: 41
Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy
Yuanfeng Zhang, Juanjuan Wu, Chaobin Zhao, et al.
Journal of Cancer (2023) Vol. 14, Iss. 5, pp. 850-873
Open Access | Times Cited: 16
Immune Checkpoint Inhibitors: A Narrative Review on PD-1/PD-L1 Blockade Mechanism, Efficacy, and Safety Profile in Treating Malignancy
Nicolas D Benelli, Ian Brandon, Karina E. Hew
Cureus (2024)
Open Access | Times Cited: 4
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
Annapaola Mariniello, Maxime Borgeaud, Marc Weiner, et al.
BioDrugs (2025)
Open Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Traitement standard de première ligne des carcinomes bronchiques non à petites cellules métastatiques sans addiction oncogénique
Romane Gille, M. Pérol
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S64-3S74
Closed Access
Exosomal PD-L1 in non-small cell lung Cancer: Implications for immune evasion and resistance to immunotherapy
Mojtaba Tarin, Mahsa Akbari Oryani, Hossein Javid, et al.
International Immunopharmacology (2025) Vol. 155, pp. 114519-114519
Closed Access
Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis
Zhe Zhao, Weike Zhang, Longbin Pang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis
Jianxiong Lai, Xiaohong Kuang, Yi Fu, et al.
Immunotherapy (2024) Vol. 16, Iss. 7, pp. 481-495
Closed Access | Times Cited: 3
Dual immunotherapy in advanced or metastatic non-small cell lung cancer: A network meta-analysis
Yuanyuan Yang, Dao Xin, Lulu Guan, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27576-e27576
Open Access | Times Cited: 3
The role of immunotherapy in early-stage and metastatic NSCLC
Attila Lieber, Attila Makai, Zsuzsanna Orosz, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 3
Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
Pedro De Marchi, Letícia Ferro Leal, Luciane Sussuchi da Silva, et al.
Translational Oncology (2023) Vol. 39, pp. 101818-101818
Open Access | Times Cited: 7
Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase III randomized clinical trials
Xiaohong Kuang, Run Xu, Jian Li
Critical Reviews in Oncology/Hematology (2024) Vol. 198, pp. 104357-104357
Closed Access | Times Cited: 2
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer
Ying Cheng, Qing Zhou, Baohui Han, et al.
Lung Cancer (2023) Vol. 178, pp. 87-95
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top